Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1223Neoplasms 1041Carcinoma, Non-Small-Cell Lung 755Prostatic Neoplasms 693Colorectal Neoplasms 593Lung Neoplasms 574Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 399Neoplasm Metastasis 387Multiple Myeloma 374Ovarian Neoplasms 372Stomach Neoplasms 317Carcinoma, Hepatocellular 303Melanoma 282Recurrence 281Brain Neoplasms 281Squamous Cell Carcinoma of Head and Neck 268Head and Neck Neoplasms 237Endometrial Neoplasms 235Glioblastoma 234Triple Negative Breast Neoplasms 230Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Uterine Cervical Neoplasms 225Lymphoma 224Hematologic Neoplasms 200Sarcoma 199Urinary Bladder Neoplasms 197Esophageal Neoplasms 191Carcinoma, Renal Cell 190Lymphoma, Non-Hodgkin 176

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced NUT Carcinoma × 1 year × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡